The anti-inflammatory effects of the second-generation antihistamines

Dermatologic Therapy

Volumn 13, Issue 4, 2000, Pages 349-360

  Walsh, G M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antihistamines; Eosinophil; ICAM 1; Mast cell

Indexed keywords

ACRIVASTINE; ALLERGEN; ANTIHISTAMINIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; AZELASTINE; CETIRIZINE; CHEMOKINE; CHLORPHENIRAMINE; CLARITIN D; CLEMASTINE; CYTOKINE; DEXCHLORPHENIRAMINE; DEXCHLORPHENIRAMINE MALEATE; EBASTINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HYDROXYICOSATETRAENOIC ACID; IMMUNOGLOBULIN E; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE; LORATADINE; MIZOLASTINE; PHOSPHOLIPASE A2; PROMETHAZINE; PROSTAGLANDIN D2; SUPEROXIDE; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR; UNINDEXED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; EOSINOPHIL; HUMAN; MAST CELL; NONHUMAN; URTICARIA;

EID: 0034498938     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2000.00042.x     Document Type: Article

References (114)

1. Comparative safety of H1 antihistamines
2. H1-receptor antagonists: Comparative tolerability and safety
3. H1 receptor antagonists: Antiallergic effects in humans
4. Molecular basis of allergic disease
5. T cells and eosinophils in the pathogenesis of asthma
6. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants
7. Interleukin-5, eosinophils and disease
8. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
9. + cells in human allergic diseases
10. Bronchial epithelial cells in asthma
11. Human eosinophils: Their accumulation, activation and fate
12. Eosinophils: Structure and functions
13. Eicosanoids, cytokines and other mediators elaborated by eosinophils
14. Cytokine generation by eosinophils
15. Eosinophilic inflammation in asthma
16. The eosinophil; structure and functions
17. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed type hypersensitivity
18. A current perspective on the roles of eosinophils in dermatologic diseases
19. Skin eosinophilia in atopic patients
20. Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo
21. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet activating factor in man
22. Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-aceter release and eosinophil recruitment in human skin
23. Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late-phase reaction
24. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge
25. Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria
26. Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects
27. The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis
28. Bradykinin-induced wheal and flare in human skin is not mediated by histamine but is blocked by cetirizine
29. Effects of loratadine on anti-IgE-induced inflammation, histamine release and leukocyte recruitment in skin of atopics
30. Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin wheals and flares, and late accumulation of eosinophils
31. Cetirizine and loratadine do not inhibit codeine-induced histamine release in human skin in vivo
32. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects
33. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses
34. The effects of cetirizine on the function of inflammatory cells involved in the allergic response
35. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: Effects of cetirizine
36. Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: Effects of cetirizine
37. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge
38. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge
39. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test
40. Protective effect of terfenadine at different dosage on conjunctival provocation test
41. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma
42. Pharmacologic modulation by cetirizine of some adhesion molecules expression in psoriatic skin lesions
43. Antihistamines in the treatment of asthma
44. Terfenadine, a potent antihistamine H1-receptor antagonist in the treatment of grass pollen-sensitive asthma
45. Treatment of bronchial asthma with terfenadine; a randomised controlled trial
46. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma
47. Protective effect of cetirizine in patients suffering from pollen asthma
48. Prophylactic treatment of grass pollen-induced asthma with cetirizine
49. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma
50. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma
51. Duration of action of a single dose of azelastine in patients with chronic asthma
52. Cetirizine in patients with seasonal rhinitis and concomitant asthma: Prospective, randomised, placebo controlled trial
53. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
54. Comparison of the bronchodilatory effects of cetirizine, albuterol and both together versus placebo in patients with mild to moderate asthma
55. Is there a place for antihistamines in the treatment of perennial asthma?
56. Allergic bronchial asthma treated with loratadine
57. Effect of a non-sedative antihistamine (loratadine) in moderate asthma. A double-blind, controlled clinical crossover trial
58. Lack of effect of loratadine on moderate to severe asthma
59. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma
60. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years
61. Prevention of asthma by ketotifen in infants with atopic dermatitis
62. Prevention of asthma with ketotifen in pre-asthmatic children: A three year follow up study
63. Allergic factors associated with the development of asthma and the influence of cetirizine on this progression in a double-blind, randomised, placebo-controlled trial: First results of ETAC
64. Prospective long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis
65. H1 receptor antagonists: Antiallergic effects in vitro
66. New insights into the second generation antihistamines
67. Inhibitory effect of azelastine on superoxide generation from activated inflammatory cells measured by a simple chemiluminescence method
68. Effects of azelastine on neutrophil chemotaxis, phagocytosis and oxygen radical production
69. Effects of various drugs on superoxide generation, arachidonic acid release and phospholipase A2 in polymorphonuclear leukocytes
70. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine
71. In vitro effects of Hi-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin
72. Loratadine, an anti-histamine, blocks antigen and ionophore-induced leukotriene release from human lung in vitro
73. Platelet aggregation and histamine release by immunological stimuli
74. Cetirizine exerts anti-inflammatory effects on human neutrophils
75. In vitro effect of cetirizine on PGE2 release by rat peritoneal macrophages and human monocytes
76. Effect of loratadine on human eosinophil function in vitro
77. Effect of terfenadine on human eosinophil and neutrophil chemotactic response and generation of superoxide
78. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetírizine)
79. Inhibitíon of human eosínophíl chemotaxis and of the IgE-dependent stímulation of human blood platelets by cetirízine
80. Cetírizine inhibits the in vitro and ex vivo chemotactic responses of T lymphocytes and monocytes
81. The anti-inflammatory effects of cetirizine
82. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis
83. Modulation of human eosinophil chemotaxis and adhesion by antiallergic drugs in vitro
84. Effects of cetirizine on human eosinophil and neutrophil activation in vitro
85. Effect of cetirizine on human eosinophil superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro
86. Leukotriene B4 in inflammation
87. Leukotriene B4 levels in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy
88. Leukotriene B4 production by blood neutrophils in allergic rhinitis-effects of cetirizine
89. + levels and leukotriene release: Novel mechanisms of action independent of the anti-histamine activity
90. Non-H1 receptor effects of antihistamines
91. A study of the interaction between cetirizine and plasma membrane of eosinophils, neutrophils, platelets and lymphocytes using a fluorescence technique
92. G-proteins in allergy
93. k B activation involved in generation of cytokines and nitric oxide
94. Additional properties of cetirizine, a new H1 antagonist
95. Inhibitory effect of cetírizíne on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma
96. Effect of cetirizine, a new H1 antihistamíne, on the early and late allergic reactions in a bronchial provocation test with allergen
97. Effect of cetirizine on nasal polyps and their associated symptoms [abstract]
98. Cetirizine treatment of allergic cough in children with pollinosis [abstract]
99. Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis
100. Continuous versus on demand treatment with cetirizine for allergic rhinitis
101. Cetirizine treatment of rhinitis in children with pollen allergy: Evidence of its antiallergic activity
102. The effect of cetirizine on sulfido leukotriene production by blood leukocytes in children with allergic rhinitis
103. The effect of a 1-week administration of cetirizine on the chemotaxis and superoxide anion production of neutrophils from healthy volunteers
104. Effects of antihistamines on inflammatory mediators
105. Loratadine reduces ICAM-1 expression on conjunctiva after specific challenge in pollen allergic patients
106. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression
107. The effect of loratadine on activated cells of the nasal mucosa in patients with allergic rhinitis
108. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy
109. Effect of ebastine on mosquito bites
110. Ebastine has more than an antihistamine effect
111. Inhibitory effect of oral mizolastine (M) on in vivo antigen-induced soluble ICAM-1 release in human skin (skin chamber technique)
112. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity
113. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity
114. Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions